FDA Approves United Therapeutics (UTHR) ADCIRCA Tablets for the Treatment of Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR) announced that the FDA has approved ADCIRCA (tadalafil) tablets for oral administration, with a recommended dose of 40 mg, as the first once-daily phosphodiesterase type 5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension (PAH). ADCIRCA is indicated to improve exercise ability in WHO Group I PAH patients, which encompasses patients with multiple forms of PAH including etiologies such as idiopathic and familial PAH as well as PAH associated with scleroderma and congenital heart disease.

"Today, thanks to the clinical development efforts led by Eli Lilly & Company, we are thrilled to make available an effective, convenient and economical therapy for PAH patients," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "The FDA's action in approving once-a-day ADCIRCA is a big plus for all three P's: patients, physicians and payors."

Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!

You May Also Be Interested In

• Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
• Repros Therapeutics (RPRX) Modifies Pivotal Androxal Protocol
• Mylan (MYL) Unit Launches Generic Viramune Tabs

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter